UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Considerations of Australian community pharmacists in the provision and implementation of cognitive pharmacy services: a qualitative study

BMC health services research, 2021-09, Vol.21 (1), p.1-906, Article 906

2021

Volltextzugriff (PDF)

‘Like building a plane and flying it all in one go’: an interview study of infection prevention and control in Australian general practice during the first 2 years of the SARS-CoV-2 pandemic

BMJ open, 2022-09, Vol.12 (9), p.e061513-e061513

2022

Volltextzugriff (PDF)

Australian community pharmacy service provision factors, stresses and strains: A qualitative study

Exploratory research in clinical and social pharmacy, 2023-03, Vol.9, p.100247-100247, Article 100247

2023

Volltextzugriff (PDF)

Mapping Australian pharmacy school curricula for content related to pharmacogenomics

Exploratory research in clinical and social pharmacy, 2022-12, Vol.8, p.100192-100192, Article 100192

2022

Volltextzugriff (PDF)

Instruments measuring community pharmacist role stress and strain measures: A systematic review

Research in social and administrative pharmacy, 2021-06, Vol.17 (6), p.1029-1058

Yong, Faith R.

2021

Volltextzugriff (PDF)

“We’re trained to trust our patients”: a qualitative study on the general practitioners’ trust in patients for colorectal cancer shared care

Family practice, 2023-10

2023

Volltextzugriff (PDF)

Factors affecting community pharmacist work: A scoping review and thematic synthesis using role theory

Research in social and administrative pharmacy, 2020-02, Vol.16 (2), p.123-141

2020

Volltextzugriff (PDF)

A participatory research approach in community pharmacy research: The case for video-reflexive ethnography

Research in social and administrative pharmacy, 2022-01, Vol.18 (1), p.2157-2163

2022

Volltextzugriff (PDF)

Provision of Community Pharmacy Services: The Pharmacist Role System, Strain and Identity

Yong, Faith R

2021

Volltextzugriff (PDF)

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

The lancet oncology, 2021-03, Vol.22 (3), p.e105-e118

2021

Volltextzugriff (PDF)

Functional and Promiscuity Studies of Three-Residue Cyclophane Forming Enzymes Show Nonnative C–C Cross-Linked Products and Leader-Dependent Cyclization

ACS chemical biology, 2024-03, Vol.19 (3), p.774-783

2024

Volltextzugriff (PDF)

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Nature communications, 2018-09, Vol.9 (1), p.3707-10, Article 3707

2018

Volltextzugriff (PDF)

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

British journal of haematology, 2015-08, Vol.170 (3), p.336-348

2015

Volltextzugriff (PDF)

Characterization of Large Structural Genetic Mosaicism in Human Autosomes

American journal of human genetics, 2015-03, Vol.96 (3), p.487-497

2015

Volltextzugriff (PDF)

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Blood, 2018-11, Vol.132 (Supplement 1), p.802-802

2018

Volltextzugriff (PDF)

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Nature communications, 2019-01, Vol.10 (1), p.213-213, Article 213

2019

Volltextzugriff (PDF)

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Blood, 2016-12, Vol.128 (22), p.3321-3321

2016

Volltextzugriff (PDF)

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK one randomized dose selection trial

British journal of haematology, 2015-08, Vol.170 (3), p.336-348

2015

Volltextzugriff (PDF)

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Blood, 2013-11, Vol.122 (21), p.1967-1967

2013

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)
Dissertationen
(1)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(6)
Pharmacology & Pharmacy
(5)
Female
(3)
Male
(3)
Medicin Och Hälsovetenskap
(3)
Multiple Myeloma
(3)
Oncology
(3)
Public, Environmental & Occupational Health
(3)
Role Theory
(3)
Aged
(2)
Basic Medicine
(2)
Cancer And Oncology
(2)
Cancer Och Onkologi
(2)
Clinical Medicine
(2)
Community Pharmacist
(2)
Community Pharmacy
(2)
Covid-19
(2)
General & Internal Medicine
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Considerations of Australian community pharmacists in the provision and implementation of cognitive pharmacy services: a qualitative study

‘Like building a plane and flying it all in one go’: an interview study of infection prevention and control in Australian general practice during the first 2 years of the SARS-CoV-2 pandemic

Australian community pharmacy service provision factors, stresses and strains: A qualitative study

Mapping Australian pharmacy school curricula for content related to pharmacogenomics

Instruments measuring community pharmacist role stress and strain measures: A systematic review

“We’re trained to trust our patients”: a qualitative study on the general practitioners’ trust in patients for colorectal cancer shared care

Factors affecting community pharmacist work: A scoping review and thematic synthesis using role theory

A participatory research approach in community pharmacy research: The case for video-reflexive ethnography

Provision of Community Pharmacy Services: The Pharmacist Role System, Strain and Identity

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Functional and Promiscuity Studies of Three-Residue Cyclophane Forming Enzymes Show Nonnative C–C Cross-Linked Products and Leader-Dependent Cyclization

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

Characterization of Large Structural Genetic Mosaicism in Human Autosomes

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK one randomized dose selection trial

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Suchergebnisse filtern